Liquidia Co. (NASDAQ:LQDA) Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Liquidia Co. (NASDAQ:LQDA) by 13.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 172,172 shares of the company’s stock after buying an additional 20,171 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Liquidia were worth $2,116,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in LQDA. Steward Partners Investment Advisory LLC purchased a new stake in Liquidia during the fourth quarter valued at about $59,000. EntryPoint Capital LLC acquired a new stake in Liquidia during the 4th quarter worth approximately $154,000. Walleye Trading LLC raised its holdings in Liquidia by 54.7% in the third quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock valued at $132,000 after buying an additional 4,670 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Liquidia in the fourth quarter valued at approximately $169,000. Finally, Arizona State Retirement System lifted its position in Liquidia by 20.3% during the fourth quarter. Arizona State Retirement System now owns 15,888 shares of the company’s stock valued at $187,000 after buying an additional 2,685 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 22,343 shares of Liquidia stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the completion of the transaction, the chief executive officer now owns 1,019,177 shares of the company’s stock, valued at $12,005,905.06. The trade was a 2.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the sale, the insider now directly owns 267,943 shares in the company, valued at $3,483,259. This trade represents a 0.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,245 shares of company stock valued at $843,326 over the last three months. 30.10% of the stock is owned by insiders.

Liquidia Stock Down 1.6 %

Shares of NASDAQ LQDA opened at $14.51 on Wednesday. The business has a 50 day moving average price of $15.16 and a two-hundred day moving average price of $12.51. The firm has a market cap of $1.24 billion, a PE ratio of -8.90 and a beta of 0.07. Liquidia Co. has a fifty-two week low of $8.26 and a fifty-two week high of $16.81.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The company had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million. On average, analysts anticipate that Liquidia Co. will post -1.51 earnings per share for the current year.

Analysts Set New Price Targets

LQDA has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research report on Thursday, March 20th. Needham & Company LLC raised their price objective on Liquidia from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. Scotiabank restated an “outperform” rating on shares of Liquidia in a research note on Thursday, March 20th. Finally, Wells Fargo & Company assumed coverage on Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target for the company. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $26.63.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).